STING agonist mechanism of action

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=iBvNOgwzfvI

Our STING agonist is a small molecule that binds to the stimulator of interferon (IFN) genes (STING). The STING agonist is delivered directly into the tumour, activating the c-GAS STING DNA sensing pathway, initiating an immune response via the production of IFNβ by tumour-associated stromal cells. This leads to the activation of dendritic cells, thereby driving T-cell priming and recruitment into the tumour microenvironment. • The STING agonist is an investigational compound and has not been approved. Its safety and efficacy has not been established. • To find out more about ongoing clinical trials in cancer please go to: https://www.mystudywindow.com/trials/... • Click on the red button above to subscribe to our YouTube channel. • Taking cancer on through the power of the body’s immune system offers exciting potential. We are driven to develop first-in-class immuno-oncology treatments with breakthrough potential. Our focus, passion and commitment, combined with our strong collaborations, will help us transform expectations, give hope to more patients and help win the fight against cancer.

#############################

New on site